A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single- Ascending Doses of MEDI6012 in Subjects With Stable Coronary Artery Disease

Trial Profile

A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single- Ascending Doses of MEDI6012 in Subjects With Stable Coronary Artery Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs MEDI 6012 (Primary)
  • Indications Coronary artery disease
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors MedImmune
  • Most Recent Events

    • 17 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 11 Nov 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2016.
    • 11 Nov 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top